Trial · NCT01678313
Results by group36
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 36
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in the Serum Prostate Specific Antigen (PSA) Level | Study Group | Baseline | 10.8 | Standard Deviation 5.42 | ng/mL |
| Change From Baseline in the Serum Prostate Specific Antigen (PSA) Level | Control Group | Baseline | 15.2 | Standard Deviation 12.7 | ng/mL |
| Change From Baseline in the Serum Prostate Specific Antigen (PSA) Level | Study Group | 3 months | 9.42 | Standard Deviation 5.41 | ng/mL |
| Change From Baseline in the Serum Prostate Specific Antigen (PSA) Level | Control Group | 3 months | 13.5 | Standard Deviation 10.6 | ng/mL |
| Change From Baseline in the Serum Prostate Specific Antigen (PSA) Level | Study Group | Change | -1.43 | Standard Deviation 0.01 | ng/mL |
| Change From Baseline in the Serum Prostate Specific Antigen (PSA) Level | Control Group | Change | -1.70 | Standard Deviation 2.15 | ng/mL |
| Change From Baseline in the Void Volume (VV) | Study Group | Baseline | 259 | Standard Deviation 113 | mL |
| Change From Baseline in the Void Volume (VV) | Control Group | Baseline | 175 | Standard Deviation 107 | mL |
| Change From Baseline in the Void Volume (VV) | Study Group | 3 months | 227 | Standard Deviation 80.8 | mL |
| Change From Baseline in the Void Volume (VV) | Control Group | 3 months | 231 | Standard Deviation 134 | mL |
| Change From Baseline in the Void Volume (VV) | Study Group | Change | -32.3 | Standard Deviation 32.1 | mL |
| Change From Baseline in the Void Volume (VV) | Control Group | Change | 55.7 | Standard Deviation 27.3 | mL |
| Change From Baseline in the Maximum Flow Rate (Qmax) | Study Group | Baseline | 12.2 | Standard Deviation 4.67 | mL/s |
| Change From Baseline in the Maximum Flow Rate (Qmax) | Control Group | Baseline | 10.0 | Standard Deviation 6.2 | mL/s |
| Change From Baseline in the Maximum Flow Rate (Qmax) | Study Group | 3 months | 12.2 | Standard Deviation 4.19 | mL/s |
| Change From Baseline in the Maximum Flow Rate (Qmax) | Control Group | 3 months | 11.9 | Standard Deviation 6.61 | mL/s |
| Change From Baseline in the Maximum Flow Rate (Qmax) | Study Group | Change | -0.09 | Standard Deviation 0.49 | mL/s |
| Change From Baseline in the Maximum Flow Rate (Qmax) | Control Group | Change | 1.9 | Standard Deviation 0.41 | mL/s |
| Change From Baseline in the IPSS Subscore (IPSS Voiding) Questionnaires | Study Group | Baseline | 7.55 | Standard Deviation 6.84 | units on a scale |
| Change From Baseline in the IPSS Subscore (IPSS Voiding) Questionnaires | Control Group | Baseline | 5.54 | Standard Deviation 5.12 | units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01678313/results